🟢 Abcellera Biologics is trading 11.47% up today after announcing an ABCL635 Phase 2 data presentation

Abcellera Biologics is trading at $13.01, up +11.47%, after announcing on September 16, 2026, that it will present Phase 2 data for ABCL635 at the International Menopause Society World Congress on October 1, covering efficacy and safety in menopausal hot-flash symptoms.

• Phase 2 ABCL635 presentation is the primary company-specific catalyst.
• Broader biotech-sector strength and improving risk appetite add momentum.